Literature DB >> 22528229

Expression and significance of SHP-2 in human papillomavirus infected cervical cancer.

Fei Meng1, Xiaoyun Zhao2, Shulan Zhang3.   

Abstract

This study investigated the expression and prognostic value of SHP-2 in cervical cancer caused by human papillomavirus (HPV) infection. Forty-five specimens from patients with cervical cancer (stage I-III), 32 specimens from patients with cervical intraepithelial neoplasia (CIN) (I, II) and 20 normal cervical samples from patients with hysteromyoma were collected in Department of Pathology for comparison. The expression levels of SHP-2 and IFN-β proteins were detected by using immunohistochemistry. The mRNA expression level of SHP-2 was detected by using quantitative real-time polymerase chain reaction (PCR). HPVs were detected by HPV GenoArray Test. The Spearman correlation was used to compare the expression level of SHP-2 in HPV infected cervical cancer vs non-HPV infected normal cervix. The level of SHP-2 protein expression in the cancer tissues (88.8%) was significantly higher than in CIN tissues (62.5%) and normal cervixes (45%) (P<0.05 and P<0.05, respectively). The SHP-2 mRNA levels in the cancer tissues were upregulated as compared with those in the normal cervixes (P<0.05). Twenty-one (46.7%) cervical cancers, 25 (78.1%) CINs and 17 (85%) normal cervixes showed IFN-β positive staining in cytoplasm. There was statistically significant difference in the expression rate of IFN-β between cervical cancer and normal cervix (χ (2)=8.378, P<0.05) as well as between cervical cancer and CIN (χ (2)=7.695, P<0.05). HPV16/18 infections could be found in normal cervixs (15%), CINs (68.7%) and cervical cancers (84.4%). There was a correlation between HPV infection and SHP-2 expression in cervical cancer (r (s)=0.653, P<0.05). SHP-2 may be a useful prognostic and diagnostic indicator for HPV infected cervical cancer. In cervical cancers, SHP-2 mRNA and protein overexpression was associated with IFN-β lower-expression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22528229     DOI: 10.1007/s11596-012-0044-4

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  26 in total

Review 1.  The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions.

Authors:  C K Qu
Journal:  Cell Res       Date:  2000-12       Impact factor: 25.617

Review 2.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

3.  Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality.

Authors:  Yuehai Ke; Eric E Zhang; Kazuki Hagihara; Dongmei Wu; Yuhong Pang; Rüdiger Klein; Tom Curran; Barbara Ranscht; Gen-Sheng Feng
Journal:  Mol Cell Biol       Date:  2007-07-23       Impact factor: 4.272

4.  Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation.

Authors:  W Vogel; R Lammers; J Huang; A Ullrich
Journal:  Science       Date:  1993-03-12       Impact factor: 47.728

5.  Molecular basis of T cell inactivation by CTLA-4.

Authors:  K M Lee; E Chuang; M Griffin; R Khattri; D K Hong; W Zhang; D Straus; L E Samelson; C B Thompson; J A Bluestone
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

6.  Beta-catenin expression is altered in human colonic aberrant crypt foci.

Authors:  X P Hao; T G Pretlow; J S Rao; T P Pretlow
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

7.  Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway.

Authors:  M You; D H Yu; G S Feng
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

8.  IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.

Authors:  Katherine A Fitzgerald; Sarah M McWhirter; Kerrie L Faia; Daniel C Rowe; Eicke Latz; Douglas T Golenbock; Anthony J Coyle; Sha-Mei Liao; Tom Maniatis
Journal:  Nat Immunol       Date:  2003-05       Impact factor: 25.606

9.  Lysosome-associated small Rab GTPase Rab7b negatively regulates TLR4 signaling in macrophages by promoting lysosomal degradation of TLR4.

Authors:  Yuzhen Wang; Taoyong Chen; Chaofeng Han; Donghua He; Haibo Liu; Huazhang An; Zhen Cai; Xuetao Cao
Journal:  Blood       Date:  2007-03-29       Impact factor: 22.113

Review 10.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

View more
  5 in total

1.  Increased expression of tyrosine phosphatase SHP-2 in Helicobacter pylori-infected gastric cancer.

Authors:  Jing Jiang; Mei-Shan Jin; Fei Kong; Yin-Ping Wang; Zhi-Fang Jia; Dong-Hui Cao; Hong-Xi Ma; Jian Suo; Xue-Yuan Cao
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

Review 2.  Functions of Shp2 in cancer.

Authors:  Jie Zhang; Fei Zhang; Ruifang Niu
Journal:  J Cell Mol Med       Date:  2015-06-19       Impact factor: 5.310

3.  Phosphotyrosine profiling of curcumin-induced signaling.

Authors:  Gajanan Sathe; Sneha M Pinto; Nazia Syed; Vishalakshi Nanjappa; Hitendra S Solanki; Santosh Renuse; Sandip Chavan; Aafaque Ahmad Khan; Arun H Patil; Raja Sekhar Nirujogi; Bipin Nair; Premendu Prakash Mathur; T S Keshava Prasad; Harsha Gowda; Aditi Chatterjee
Journal:  Clin Proteomics       Date:  2016-06-15       Impact factor: 3.988

4.  Clinical significance of leukocyte-associated immunoglobulin-like receptor-1 expression in human cervical cancer.

Authors:  Yue Wang; Xueshan Zhang; Fang Miao; Yanning Cao; Jiangnan Xue; Qizhi Cao; Xiaoshu Zhang
Journal:  Exp Ther Med       Date:  2016-10-26       Impact factor: 2.447

5.  Alterations of cell cycle control proteins SHP‑1/2, p16, CDK4 and cyclin D1 in radioresistant nasopharyngeal carcinoma cells.

Authors:  Gang Peng; Ru-Bo Cao; Yue-Hua Li; Zhen-Wei Zou; Jing Huang; Qian Ding
Journal:  Mol Med Rep       Date:  2014-08-07       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.